I
István Rácz
Researcher at University of Debrecen
Publications - 66
Citations - 1316
István Rácz is an academic researcher from University of Debrecen. The author has contributed to research in topics: Capsule endoscopy & Population. The author has an hindex of 15, co-authored 65 publications receiving 1185 citations. Previous affiliations of István Rácz include Hungarian Natural History Museum.
Papers
More filters
Journal ArticleDOI
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
William J. Sandborn,Subrata Ghosh,Julián Panés,Ivana Vranic,Wenjin Wang,Wojciech Niezychowski,Severine Vermeire,Olivier Dewit,Harald Peeters,Jiri Stehlik,Tomas Vanasek,David Laharie,Jean-Frederic Colombel,Marc-André Bigard,Marta Varga,Margit Zeher,Janos Novak,Béla Hunyady,Ágnes Salamon,István Rácz,Paolo Gionchetti,Anna Kohn,Cosimo Prantera,Pieter C. F. Stokkers,Maria Slomka,Leszek Paradowski,Tomasz Arlukowicz,Ladislav Kuzela,Boris Baricky,Tibor Hlavaty,Maria Isabel Vera,Jordi Guardiola,Chris Probert,Jonathan Shaffer,Mark R. Fleisher,Ronald E. Pruitt,John Sawyer Goff,John Weber,Raymond Lloyd Bell,Andrew Harrison Zwick,Alexandra Gutierrez,Robert H. Levine,Stephen Brett Hanauer,Lori Ann Lavelle,Ravindranath K. Kottoor,Gerald W. Dryden,Robert Hardi,David Vaughn Glorioso,Prabhakar Swaroop,Scott D. Lee,Teressa Joan Patrick,Sheldon Scheinert,Charles A. Sninsky,Seymour Katz,Mark D. Noar,Michael Marion Gaspari,Glenn L. Gordon,Thomas A. Dalton,Douglas Edward Homoky,William Ransom Kilgore,Joel A. Levien,Herbert R. Schneider,Suleman Abdul Moola,Frederik Cornelius Kruger,John P. Wright,Nazimuddin Aboo +65 more
TL;DR: There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib or placebo twice daily.
Journal ArticleDOI
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
Walter Reinisch,Williem de Villiers,László Bene,László Simon,István Rácz,Seymour Katz,István Altorjay,Brian G. Feagan,Dennis Riff,Charles N. Bernstein,Daniel W. Hommes,Paul Rutgeerts,Antoine Cortot,Michael Marion Gaspari,May Cheng,T. Pearce,Bruce E. Sands +16 more
TL;DR: Although a strong clinical response to fontolizumab was not observed, significant decreases in C‐reactive protein levels suggest a biological effect.
Journal ArticleDOI
Characterizing the importance of habitat patches and corridors in maintaining the landscape connectivity of a Pholidoptera transsylvanica (Orthoptera) metapopulation
TL;DR: In this article, the authors proposed a method to quantify the relative importance of habitat patches and corridors in maintaining landscape connectivity, which explicitly considers pure topological properties and topographical measures, like the quality of both patches (local population size) and corridors (permeability).
Journal ArticleDOI
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease
Satish Keshav,Tomáš Vaňásek,Yaron Niv,Robert Petryka,Stephanie Howaldt,Mauro Bafutto,István Rácz,D. J. Hetzel,Ole Haagen Nielsen,Severine Vermeire,Walter Reinisch,Per Karlén,Stefan Schreiber,Thomas J. Schall,Pirow Bekker +14 more
TL;DR: Encouraging results from this clinical trial led to initiation of Phase 3 clinical trials in Crohn’s disease.
Journal ArticleDOI
Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
Wolfgang Kruis,Laimas Virginijus Jonaitis,Juris Pokrotnieks,T. L. Mikhailova,Marek Horynski,M. Bátovský,Y. S. Lozynsky,Y. Zakharash,István Rácz,K. Kull,Aleksandar Včev,M. Faszczyk,Karin Dilger,Roland Greinwald,Ralph Mueller +14 more
TL;DR: Aliment Pharmacol Ther 2011; 33: 313–322